SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Babe Didrikson Zaharias (HR-ML038)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 18judgment calls in the dossier
- 2protocol deviations
- 3orders and referrals without results in the record
- 1evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check the MRI staging of a low rectal tumor, the choice of dostarlimab alone for mismatch repair-deficient locally advanced disease, the restaging schedule and the definition of clinical complete response, the reading of loss of MSH2 and MSH6 with a negative germline panel and two somatic MSH2 variants, the management of immune-related hypothyroidism without holding treatment, and the watch-and-wait surveillance intervals. |
| provenance review | not_started | | | She died in 1956; the recent-death rule does not apply. Claims rest on the Handbook of Texas (by her biographer Susan Cayleff), the National Women's History Museum, two Gale reference entries, the Babe Didrikson Zaharias Foundation and Wikipedia. The site of her cancer and the operation are recorded as R because the sources call it colon cancer and name no operation; everything clinical is synthetic. |
| safe messaging review | not_started | | | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative, companion or historical physician is given a role in the modern episode; her husband appears only in the documented history, and her close companion Betty Dodd is not used. |
Judgment calls (dossier editorial resolutions)
- Recent-death rule. She died in 1956, so the rule does not apply. The claims are still limited to what the fetched sources state. The USGA article on her 1954 win and Texas Monthly’s profile could not be fetched (403); the New York Times obituary was not read and is cited only through the Notable Sports Figures entry’s quotation of it; Susan Cayleff’s biography Babe was not read, and her account is used only through her Handbook of Texas entry. Britannica could not be fetched.
- Name. She is known as Babe Didrikson Zaharias; her birth name was Mildred Ella Didrikson (the family spelling was Didriksen), and she competed as Didrikson before and after her marriage. Splitting the display name at the last space would make “Babe Didrikson” her given names. The record uses identity.name_parts with given names Mildred Ella and the family name Didrikson Zaharias, so the C-CDA and FHIR names carry her legal given names and both the surname she was famous under and her married surname; the display name and the FHIR name text stay Babe Didrikson Zaharias. The notes call her Ms. Didrikson Zaharias. Aliases are Mildred Ella Didrikson, Mildred Didrikson Zaharias, Babe Didrikson and Babe Zaharias; none appears in another record. “Babe” alone is not an alias.
- Birth year. She gave 1914 on her 1932 Olympic application, and some sources and a marker at her grave give 1913 to 1915; the Handbook of Texas, the National Women’s History Museum, her gravestone and baptismal certificate give 1911, which is used (CLM-0002). The 1914 year is recorded as a conflicting alternative. The contemporary New York Times report gave her age at death as 42, which reflects the later year.
- Death date. September 27, 1956 (Handbook of Texas, foundation, New York Times report); Women in World History gives September 26, recorded as a conflicting alternative.
- Site of her cancer and the operation (R). Every source read calls it colon cancer and says the operation included a colostomy; none names the operation or gives pathology. Some popular accounts (Texas Monthly, not fetched) call it rectal cancer. That it was a low rectal cancer removed by abdominoperineal resection is recorded as R, possible (CLM-0008), because a permanent colostomy in 1953 most often followed that operation; it is linked to the modern diagnosis but not resolved by it. The modern low rectal adenocarcinoma is a teaching choice that fits the documented permanent colostomy.
- Index age and dates. The synthetic date of birth is June 26, 1984 (shift 73 years). The index visit on March 16, 2026 maps to March 16, 1953, when she was 41: after the documented fatigue at the end of the 1952 season and before the documented diagnosis in April and the operation on April 17, 1953. All visits map to March to October 1953, within her lifetime; they are not a claim about where she was. The sources place her home at the Tampa Golf and Country Club and her operation in Beaumont; the modern social history uses Tampa.
- Intake claims. Only the fatigue at the end of 1952 (CLM-0006) and earlier history appear in the intake documents. The diagnosis and operation (CLM-0007, CLM-0008) are linked to a timeline event dated April 17, 1953, and the 1954 Open, the recurrence, her cancer advocacy and her death to later events.
- Presenting problem. Rectal bleeding with a change in bowel habit and a rectal mass (K62.5) is resolved at the diagnosis visit on March 30, 2026, when low rectal adenocarcinoma (C20, both_with_link) is recorded. Iron deficiency anemia from blood loss (D50.0) is recorded at intake and stays active while iron stores are refilled. The intake documents state only what was known then.
- Mismatch repair status. The tumor is mismatch repair deficient (loss of MSH2 and MSH6, microsatellite instability high). This was chosen because it is the teaching point that most changes care for a low rectal cancer in a young athlete: PD-1 blockade with dostarlimab offers a high chance of a clinical complete response and organ preservation, sparing the abdominoperineal resection and permanent colostomy she had in 1953, and it puts mismatch repair testing of every colorectal cancer and germline testing under 50 at the center of the episode. About 5 to 10 percent of rectal cancers are mismatch repair deficient, so this is the less common case; the record says so in the teaching objective by naming total neoadjuvant therapy as the standard for proficient tumors.
- Germline result. The germline panel is negative and tumor sequencing finds two somatic MSH2 variants, by design: a positive germline result would imply a health fact about her real blood relatives. Her first-degree relatives are still advised to screen early because she had colorectal cancer young; this is a recommendation, not a statement about any of them. No relative is named, and her siblings are referred to only as the people the screening letter is for.
- Synthetic clinical picture. All visits, results, imaging, pathology, stage (cT3bN1M0), the regimen (dostarlimab 500 mg every three weeks for nine doses), the responses, the genetic and tumor results, immune-related hypothyroidism and its treatment, her height (168 cm) and weights are synthetic. Qualitative results (biopsy, mismatch repair stains, hepatitis and HIV tests, pregnancy test, genetic results, rapid respiratory tests) are in note text only.
- Sick visit. A viral upper respiratory infection (J06.9) a week before cycle 4, chosen because a new cough on PD-1 blockade must prompt a check for pneumonitis (oxygen saturation at rest and on exertion, chest X-ray), because it fits her life on tour, and because it insinuates no undocumented real diagnosis. The TSH drawn that day for two weeks of tiredness showed the first rise of immune-related thyroiditis.
- Preventive visit. A periodic adult preventive visit at 42 (CPT 99396 and 99497 in plain text) on the day of cycle 7: hepatitis B vaccination begun (negative surface antibody), first screening mammogram ordered under the 2024 USPSTF recommendation, sun protection counseling and a skin examination for an outdoor athlete, influenza and COVID-19 vaccines due in the autumn, zoster vaccine not indicated (PD-1 blockade alone is not immunosuppressive treatment), and advance care planning with an unnamed agent.
- Focused visits. The four chronic-care follow-ups (diagnosis and consultation, cycle 2, restaging after four doses, and final restaging) are documented as focused visits on the NCCN rectal cancer guideline, the ASCO locally advanced rectal cancer, germline testing and immune-related adverse event guidance, the dostarlimab trials, and the CMID colorectal cancer, hypothyroidism and anemia monographs. Synthetic findings introduced: immune-related hypothyroidism (E03.2) at the fourth visit, treated with levothyroxine while dostarlimab continued. Two protocol deviations are recorded instead of invented results: (1) the ferritin due about three months after oral iron began was not drawn at the restaging visit; no harm (bleeding stopped, hemoglobin normal); drawn at the final visit (41 ng/mL); (2) the TSH and free T4 due with the ninth dose, six weeks after the preventive visit, were not drawn; no harm (TSH 2.4 at the final visit on an unchanged dose); corrective action: thyroid tests added to the standing order sets.
- Wound-ostomy nursing and surgery. Because she reached a clinical complete response, no operation and no stoma were needed. The colorectal surgery consultation at diagnosis and the contingency plan (chemoradiation and total mesorectal excision, with stoma marking and teaching by a wound-ostomy nurse before any operation) are recorded; the wound-ostomy rows are “not indicated” with the reason.
- Consultation. The medical oncology referral and the consultation by Jun-Ho Albright-Nakamura, MD (a fictional consultant), on the diagnosis day, are S. The consultant answers the five referral questions in line with what the record shows afterwards: mismatch repair-deficient cT3bN1M0 low rectal cancer; dostarlimab for nine doses with restaging, then watch-and-wait after a clinical complete response; germline testing with tumor sequencing when negative, and early screening for first-degree relatives; immune-related adverse event monitoring (thyroiditis occurred and was treated); and continued sport, contraception and sexual health.
- Real people. George Zaharias appears only in the documented history (CLM-0004, CLM-0011). Betty Dodd, her close companion from 1950, is documented in the Handbook of Texas; she is not used, because the episode’s social history does not need her. No relative, companion or historical physician is given a role in the modern episode, and no other figure with a record in the dataset is named.
- Not used. Accounts that name a surgeon, hospital or Beaumont physician for the 1953 operation were not found in a fetchable reliable source. The Notable Sports Figures entry says she “tied as winner” of the 1954 Open; the Wikipedia biography says she won it a month after surgery; both are wrong against the championship record and are not used. Her alcohol and tobacco use, her private papers and her doctors’ records were not researched.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|
2026-06-29 Progress note 05 (C-CDA) | Ferritin after oral iron | About three months after starting | Missed: the ferritin due about three months after oral iron began was not added to the restaging blood tests. No harm is expected, because the bleeding has stopped and the hemoglobin is normal; corrective action: ferritin added to the final restaging blood tests, and iron continued until then |
2026-10-05 Progress note 07 (C-CDA) | TSH and free T4 with the ninth dose | Every six weeks on PD-1 blockade | Missed: the thyroid tests due with the ninth dose, six weeks after the preventive visit, were not on the infusion order. No harm resulted, since the TSH today, eight weeks after the last check, is in range on an unchanged dose; corrective action: thyroid tests added to her standing surveillance order set, and the infusion center's PD-1 order set reviewed so that thyroid tests repeat automatically every six weeks |
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-03-30 Progress note 02 (C-CDA) | Laboratory | Hepatitis B, hepatitis C and HIV screening | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV drawn today |
2026-03-30 Progress note 02 (C-CDA) | Laboratory | Germline multigene panel | Ordered | Sent today after counseling |
2026-08-10 Progress note 06 (C-CDA) | Prevention | Breast cancer screening | Ordered | Mammogram every two years from 40; first screening mammogram ordered |
Evidence to check
Retrospective claims (R)
| Claim | Statement | Certainty |
|---|
| CLM-0008 | The sources read call her cancer colon cancer and do not name the operation or give any pathology. That it was a low rectal cancer removed by abdominoperineal resection is a retrospective reading of the permanent colostomy, which was then the usual result of that operation; some popular accounts call it rectal cancer. | possible |
Sensitive claims
None.
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-03-16 | Hemoglobin | 11 g/dL (low) | Low |
| 2026-03-16 | MCV | 77 fL (low) | Low |
| 2026-03-16 | Platelets | 412 10*3/uL (high) | High |
| 2026-03-16 | Ferritin | 9 ng/mL (low) | Low |
| 2026-03-16 | CEA | 5.8 ng/mL (high) | High |
| 2026-03-30 | Hemoglobin | 11.1 g/dL (low) | Low |
| 2026-03-30 | Platelets | 405 10*3/uL (high) | High |
| 2026-04-27 | CEA | 3.4 ng/mL (high) | High |
| 2026-06-01 | TSH | 5.8 mIU/L (high) | High |
| 2026-06-29 | TSH | 12.6 mIU/L (high) | High |
| 2026-06-29 | Free T4 | 0.6 ng/dL (low) | Low |